SIGA
SIGA Technologies, Inc.
Set alert
3.04 USD -0.14 -4.40%
3.03 Day range 3.24
2.87 52-week range 8.43
- YTD
- -50.25%
- 1 year
- -63.42%
- Open
- 3.18
- Prev close
- 3.18
- Mkt cap
- 218.42M
- Vol
- 504.68K
- Avg vol
- 627.31K
- EPS
- -0.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.03
- High
- 3.24
- Forward P/E
- 4.79
- Beta
- 0.89
- Short ratio
- 6.64
- Inst. own
- 53.01%
- Dividend
- 0.00
- Ex-div date
- Mar 24, 2024
- 50-d avg
- 6.75
- 200-d avg
- 7.88
- 1y target
- 0.00
Key statistics
- Market cap
- 424.14M
- Enterprise value
- 324.24M
- Trailing P/E
- 4.95
- Forward P/E
- 4.79
- PEG ratio
- 0.00
- Price / sales
- 2.44
- Price / book
- 2.50
- EPS (TTM)
- 1.20
- Beta
- 0.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 49.34%
- Revenue (TTM)
- 173.73M
- Revenue growth
- 8.40%
- Free cash flow
- 54.24M
- Total cash
- 99.27M
- Total debt
- 1.51M
- Return on equity
- 58.39%
- Shares outstanding
- 71.40M
- Short % of float
- 7.97%
- 50-day average
- 6.75
- 200-day average
- 7.88
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SIGA Revenue — quarterly 41.00M
SIGA Net income — quarterly 12.46M
SIGA EPS — quarterly 0.17
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | 0.02 | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | 0.03 | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.00 | 0.14 | — | — |
| Mar 12, 2024 | Dec 1, 2023 | 0.00 | 1.01 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | -0.04 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2012 | Wedbush | main | — | Outperform |
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- siga.com
News
- SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results
- SIGA Technologies Receives ~$15M Contract From Public Services And Procurement Canada To Procure Oral TPOXX
- SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®
- Full Transcript: SIGA Technologies Q2 2026 Earnings Call
- SIGA Technologies Q2 EPS $0.17 Down From $0.49 YoY, Sales $41.002M Down From $81.120M YoY
- SIGA Technologies Q1 EPS $(0.05) Down From $(0.01) YoY, Sales $6.243M Down From $7.041M YoY
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
- Why Are Siga Technologies Shares Trading Higher?
Your note
Sign in to keep a note on SIGA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORD HAROLD EUGENE JR | Director | Conversion of Exercise of derivative security | Jun 10, 2024 | 17,298 |
| HRUBY DENNIS E | Officer | Conversion of Exercise of derivative security | Jun 30, 2024 | 169,256 |
| KNISELY EVAN A | Director | Conversion of Exercise of derivative security | Jun 10, 2024 | 17,298 |
| LUCKSHIRE DANIEL J | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 30, 2024 | 263,217 |
| MARSHALL JOSEPH W. III | Director | Conversion of Exercise of derivative security | Jun 10, 2024 | 216,283 |
| NABEL GARY J. | Director | Conversion of Exercise of derivative security | Jun 10, 2024 | 43,514 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.96% | 4,017,178 | 23.86M | Sep 29, 2024 |
| Vanguard Group Inc | 3.17% | 2,566,197 | 15.24M | Sep 29, 2024 |
| First Wilshire Securities Management Inc | 3.01% | 2,438,629 | 14.49M | Sep 29, 2024 |
| AltraVue Capital, LLC | 2.86% | 2,312,894 | 13.74M | Sep 29, 2024 |
| Hotchkis & Wiley Capital Management, LLC | 2.53% | 2,048,440 | 12.17M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.36% | 1,908,139 | 11.33M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 1,236,605 | 7.35M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.49% | 1,206,061 | 7.16M | Oct 30, 2024 |
| Avantis U.S. Small Cap Value ETF | 1.19% | 959,874 | 5.70M | Sep 29, 2024 |
| American Beacon Small Cap Value Fd | 1.05% | 849,600 | 5.05M | Oct 30, 2024 |
| Hotchkis and Wiley Small Cap Value Fund | 0.94% | 759,600 | 4.51M | Sep 29, 2024 |
| Federated Hermes MDT Small Cap Core Fund | 0.92% | 746,288 | 4.43M | Jul 30, 2024 |